ERY-TAB

Post-LOE

erythromycin

Johnson & Johnson

ANDAORALTABLET, DELAYED RELEASE

Approved

Mar 1982

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

ERY-TAB (erythromycin) by Johnson & Johnson is mechanism of action erythromycin acts by inhibition of protein synthesis by binding 50s ribosomal subunits of susceptible organisms. Approved for the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, urogenital infections during pregnancy and 5 more indications. First approved in 1982.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

Mechanism of Action Erythromycin acts by inhibition of protein synthesis by binding 50S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis.

Pharmacologic Class:

Macrolide

Indications (8)

the following infections caused by Chlamydia trachomatis : conjunctivitis of the newborn pneumonia of infancy

Worked on ERY-TAB at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (14)

NCT06948747Phase 1Completed

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

Started May 2025

49 enrolled

Healthy Participants

NCT06917872Phase 1Completed

A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood

Started Apr 2025

20 enrolled

Healthy

NCT06395610Phase 1Completed

Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers

Started Mar 2024

24 enrolled

Chronic Obstructive Pulmonary Disease

NCT06273891Phase 3Recruiting

Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes

Started Mar 2024

140 enrolled

Premature Rupture of Membrane

NCT05797753Phase 1Completed

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

Started Feb 2022

16 enrolled

Amyotrophic Lateral SclerosisHealthy Volunteer